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chizophrenia is a mental disease that affects approx-
imately 1% of the population with distressing long-term
consequences for the patient and society.There is con-
sistent evidence that the principal etiology of schizo-
phrenia involves predisposing genetic factors.
However,the search for the susceptibility genes with a
view to any form of gene therapy has proved elusive.
Furthermore,it is not clear whether the genes of familial
schizophrenia are also involved in sporadic cases,which
represent the overwhelming majority of patients with
schizophrenia. For sporadic cases, genetic association
studies comparing the distribution of allelic frequencies
of candidate genes in patients with schizophrenia and
controls have been performed,but the outcome of such
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The development of safe and effective new drug treatments for schizophrenia poses a challenging task. This class of drugs
is known to be associated with a wide range of serious and troublesome safety problems that include neurological, car-
diac, endocrine, and metabolic side effects. Many of these drugs have a narrow therapeutic index and generate metabo-
lites that often have their own unique pharmacological profile different from the parent compound. These features make
it imperative that the optimal dose schedules for neuroleptic drugs are carefully characterized. Many of these drugs are
metabolized by cytochrome P450 enzymes, which show genetic polymorphism and a bimodal distribution within the pop-
ulation. A significant subset of the population cannot eliminate these drugs as effectively as the majority. This brings an
added dimension of complexity in characterizing the dose and individualizing therapy. Many neuroleptic agents are proar-
rhythmic with an adverse effect on cardiac repolarization. They are prone to prolonging the QT interval and inducing tor-
sade de pointes. Given the potentially fatal outcome of this ventricular tachyarrhythmia, drug development programs
need to ensure that the proarrhythmic potential of any new neuroleptic agent is thoroughly explored and its proar-
rhythmic risk characterized. The clinical use of many of these drugs is further troubled by their high potential for drug–drug
interactions. These too need to be adequately investigated during development. The approval and the labeling of a new
neuroleptic agent require a careful regulatory assessment of its risk/benefit ratio in comparison with the available alter-
natives. Their safe and effective use in routine clinical practice depends on careful attention to prescribing information,
especially the contraindications, precautions, and patient-monitoring requirements. Dialogues Clin Neurosci. 2002;4:449-462.studies has not been particularly spectacular.There is
optimism that advances in molecular genetics will
increase our understanding of the progression from
genetic susceptibility to clinically overt schizophrenia.
The mainstay of managing schizophrenia at present,
however, is drug therapy. Indeed, if the susceptibility
gene with a required degree of predictive power can be
identified,but cannot be modified,there is much ethical
and clinical discussion as to whether “pharmacological
prophylaxis”of the potential patient with schizophrenia
with atypical neuroleptics ought to be initiated at the
“prodromal”stage or even earlier.
While the principles of clinical trials aimed at demon-
strating the efficacy of new neuroleptic agents are rela-
tively well established,the task of establishing their safety
still remains a challenging one. This class of drugs is
known to have a wide range of serious and troublesome
safety problems, which include neurological, cardiac,
endocrine, and metabolic side effects. Recently, devel-
oped atypical neuroleptics have succeeded in modestly
reducing these risks.
The present efficacy-orientated approach is primarily
responsible for the failure of clinical trials to detect the
risks that are likely to be encountered during the uncon-
trolled use of the drug after it is approved.The number
of patients exposed is not large enough nor are all the
patient subgroups likely to receive the drug during its
uncontrolled clinical use represented in these preap-
proval clinical trials. Despite very tight inclusion and
exclusion criteria,clinical trials with neuroleptic drugs are
among those with very high patient withdrawal rates.
It is usually the case that the subgroups excluded from clin-
ical trials are in fact those who are at a much greater risk.
These include those patients with predisposing diseases or
those receiving drugs with a potential for pharmacokinetic
or pharmacodynamic interactions. Thus, the scope for
detecting drug–disease or drug–drug interactions in clini-
cal trials is also very limited.And yet,experience has shown
that these are among the most important risk factors!
There are additional reasons why the safety of neu-
roleptic drugs should be adequately characterized.
Atypical antipsychotics have revolutionized the treat-
ment of schizophrenia, becoming the treatment of
choice for patients not only during their first episode,but
also throughout their life course.However,of particular
regulatory interest are the reports that more than 70%
of prescriptions for these drugs are written for condi-
tions other than schizophrenia, such as affective disor-
ders (both mania and depression),autism,geriatric agi-
tation, substance abuse disorder, senile dementia, and
pathologic aggression.
1,2 Atypical agents may be partic-
ularly suitable for the elderly, children, or adolescents,
who are especially susceptible to the side effects of med-
ications and in whom the risk of tardive dyskinesia (TD)
is high.
Important lessons have already been learnt from routine
clinical use of neuroleptic drugs already approved.
Therefore,there is a clear prerequisite to consider and
thoroughly explore the potential of a candidate new drug
for the hazards known to be associated with other drugs
of the same chemical,pharmacological and/or therapeu-
tic classes.In this context,the International Conference
on Harmonization (ICH) guideline
3 entitled “The Extent
of Population Exposure to Assess Clinical Safety for
Medicines Intended for Long-term Treatment of Non-
life–threatening Conditions”is helpful.The mandatory
requirement is 100 patients exposed to the new drug for
at least 12 months.For the most common adverse events,
ie,frequent and early-onset events,the guideline provides
for 1500 patients studied over 3 months and it is esti-
mated that this database will characterize a cumulative
3-month incidence of about 1% or more.This guideline
does,however,recommend that the safety database may
need to be expanded to characterize specific issues in
special circumstances.Nevertheless,potentially fatal or
otherwise serious adverse reactions usually have a fre-
quency well below that which can be detected by this size
of database.Clearly,alternative strategies are necessary
to identify the risk and the predisposing factors.
In order to facilitate the development of new chemical
entities (NCEs),including neuroleptic drugs,the European
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Selected abbreviations and acronyms
CPMP Committee for Proprietary Medicinal Products 
EMEA European Medicines Evaluation Agency 
EM extensive metabolizer
EPS extrapyramidal symptoms
FDA Food and Drug Administration
HERG human ether-a-go-go
ICH International Conference on Harmonization
IKr delayed rectifier potassium channel
NCE new chemical entity
PM poor metabolizer
SPC summary of product characteristics
TD tardive dyskinesia
TdP torsade de pointesUnion’s Committee for Proprietary Medicinal Products
(CPMP) has issued a number of notes for guidance,includ-
ing one on schizophrenia.These give a state-of-the-art sci-
entific guidance on development strategies,all aspects of
clinical trials, and the nature of the data required. In 
addition,there is a range of biostatistical guidance notes.
These can all be accessed on the website of the European
Medicines Evaluation Agency (EMEA).
4
This paper is a brief review of some of the issues that
weigh heavily during the regulatory evaluation of new
neuroleptic agents.Drugs in this pharmacotherapeutic
class attract particular attention since they have a narrow
therapeutic index and are metabolized by enzymes that
are highly polymorphic.Among the major deficiencies
encountered during the evaluation of any new neu-
roleptic agent are the identification of the optimal dose
schedule and the effect of pharmacogenetic factors on its
efficacy,as well as the safety.Other issues of concern are
characterization of its potential for proarrhythmias and
significant drug–drug interactions.
Dosing schedule
It is not infrequently the case that the dose schedules pro-
posed by the sponsors bear hardly any relationship to the
pharmacology of the drug concerned.This applies not only
to the neuroleptic drugs,but also to many other pharma-
cotherapeutic classes.When proposing a dose schedule,the
factors most relevant are the primary pharmacological
activity and half-lives of both the parent drug and its
metabolites.At times, because of the potent secondary
pharmacology of the drug (responsible for its toxicity),
there may be a compelling need for a very shallow dose
titration schedule.Two good examples of drugs requiring
gradual upward titration are pimozide and sertindole.
Pimozide is an effective neuroleptic agent that has been
on the market since 1971.It has a long mean half-life of
approximately 55 h in most individuals. This is highly
variable and may be as long as 150 h in some patients.
When first approved, its starting dosage was 2 to 4
mg/day with a slow upward titration to a maximum
dosage of 10 mg/day. Subsequently, the slow titration
schedule was removed,the starting dosage increased to
20 mg/day and the maximum dosage was increased to 60
mg/day.Following reports of QTc interval prolongation
and torsade de pointes (TdP),the recommended dosing
schedule for patients with chronic schizophrenia was
amended to a starting dosage of 2 mg/day.Subsequent
titration was to be slow and shallow,with increases of 2
to 4 mg in the daily dose being made at weekly intervals
or longer.The maximum dosage was reduced from 60 to
20 mg/day. In 1981, trials investigating the use of
pimozide in schizophrenia in the USA had to be sus-
pended following the sudden deaths of two patients dur-
ing acute titration of pimozide to 70 to 80 mg/day.
5 In the
USA,pimozide is not approved for use in schizophrenia;
it was approved in 1984 only for use in Tourette’s syn-
drome.
Sertindole is one of the relatively new,atypical antipsy-
chotic agents.It was introduced onto the market in 1995.
It has powerful α-adrenoceptor–blocking activity and an
acute administration of a single dose of 8 mg or more can
result in marked orthostatic hypotension. Initiation of
therapy with sertindole, therefore, requires a starting
dosage of 4 mg/day. Sertindole is metabolized by the
cytochrome P450 enzyme CYP2D6 and exhibits a high
interindividual variability of metabolism. Its half-life
ranges from 60 to 100 h,and a given dose requires well
over 10 days for steady-state plasma concentration to be
reached.Therefore,the dosing scheme approved requires
that the dose should be increased in 4 mg increments
after 4 to 5 days on each dose to the optimal mainte-
nance dosage range of 12 to 20 mg/day.Depending upon
individual patient response,the dosage may be increased
to a maximum of 24 mg/day. Patients’ blood pressure
should be monitored during the period of dose titration
and during the early part of maintenance treatment.The
dosing section warns,“A starting dose of 8 mg or a rapid
increase in dose carries a significant risk of severe
hypotension.”Despite its otherwise favorable profile in
terms of extrapyramidal side effects, this shallow dose
titration renders the drug worthless for use in acute situ-
ations.
In one study,all 499 labels of drugs approved by the US
Food and Drug Administration (FDA) between 1
January 1980 and 31 December 1999 were examined for
significant dose changes.
6Time- and covariate-adjusted
risks for dosage changes by 5-year epoch and therapeu-
tic groups were estimated by survival analysis.Of the 499
NCEs, 354 (71%) were evaluable. Dosage changes in
indicated populations occurred in 73 NCEs (21%). A
total of 58 (79%) were safety-motivated, net dosage
decreases.The percentage of NCEs with changes by ther-
apeutic group ranged from 27.3% for neuropharmaco-
logic drugs to 13.6% for miscellaneous drugs. Median
time to change following approval fell from 6.5 years
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451(1980-1984) to 2.0 years (1995-1999). 1995-1999 NCEs
were 3.15 times more likely to change in comparison to
1980-1984 NCEs (P=0.008,Cox analysis).
When developing new antipsychotic agents,therefore,it is
advisable that the dose-finding phase 2 studies explore a
range of doses from 25% to at least 200% of the likely
dose,and then proceed to the pivotal phase 3 studies with
at least two doses.The ICH guideline on “Dose-Response
Information to Support Drug Registration”
7 describes how
helpful is the knowledge of the shape of individual
dose–response curves,and it distinguishes these from the
population curve.The guideline clearly cautions:
“Choice of a starting dose might also be affected by poten-
tial intersubject variability in pharmacodynamic response
to a given blood concentration level, or by anticipated
intersubject pharmacokinetic differences, such as could
arise from nonlinear kinetics,metabolic polymorphisms
or a high potential for pharmacokinetic drug–drug inter-
actions”
and recommends that in utilizing dose–response infor-
mation,the influences of various demographic features,
individual characteristics (including metabolic differ-
ences), and concurrent drugs and diseases should be
identified as far as possible.
The dosing scheme should identify the unit dose,daily
frequency of administration,maximum daily dose,and
the dose titration schedule.The influence of pharmaco-
genetics in determining the optimal dose for a subgroup
of patients,discussed below,may have to be explored and
justified in the regulatory submission.
Pharmacogenetic influences on drug response
The two components of a dose–response curve—phar-
macokinetics and pharmacodynamics—are both subject
to high interindividual variability.Although a number of
factors such as age,gender,presence of comorbidity,and
administration of comedications may modulate these two
components,they are under powerful genetic influences.
These genetic influences act by regulating the expression
of drug-metabolizing enzymes (pharmacokinetic vari-
ability) or the function of various pharmacological tar-
gets (pharmacodynamic variability). The presence of
variant alleles often exerts influences that far exceed
those due to the other factors.It is therefore not surpris-
ing that the safety and efficacy of some drugs in an indi-
vidual patient are often determined largely by the genetic
profile (genotype) of the patient.
With the completion of the Human Genome Project and
advances in biotechnology,which promise the prospects
of characterizing genetic variations in individual patients
rapidly and cheaply,expectations are rising that therapy
individualized on the basis of a patient’s genotype may
become a reality within the next few years.The applica-
tion of pharmacogenetics during drug development and
regulatory evaluation has gathered momentum as a
result of this anticipated revolution in therapeutics over
the course of next decade.Arising from these genetically
driven interindividual differences in pharmacology,areas
of new drug applications that are likely to attract close
regulatory scrutiny include the investigation of genetic
influences on dose–response relationships and the rec-
ommended dose schedules.
The genetic polymorphism most thoroughly character-
ized and also directly relevant to the use of neuroleptic
drugs is that of drug-metabolizing enzyme, CYP2D6.
Although CYP2D6 accounts for only 2% of the total
liver cytochrome P450 content,it is responsible for the
metabolism of well over 20% of the drugs eliminated by
metabolic clearance.
8 It has been shown to control the
oxidative biotransformation of well over 60 drugs to date,
which include antiarrhythmics,β-blockers,antihyperten-
sives,antianginals,neuroleptics,antidepressants,and anal-
gesics,as well as a number of other miscellaneous drugs.
8,9
Similarly, clinically relevant polymorphisms have also
been described for other drug-metabolizing enzymes
such as cholinesterase, N-acetyltransferase (NAT2),
dihydropyrimidine dehydrogenase (DPD), CYP2C9,
CYP2C19,and thiopurine methyltransferase (TPMT).
However, these seem to be far less important for neu-
roleptic drugs.
Studies over the last 25 years have shown that,depending
on their ability to mediate CYP2D6-dependent hydroxyl-
ation of the antihypertensive drug debrisoquine,a given
population may be divided into two phenotypes:extensive
metabolizers (EMs) or poor metabolizers (PMs).
10 This
polymorphism results from autosomal recessive inheri-
tance,in a simple Mendelian fashion,of alleles at a single
locus mapped to chromosomal region 22q13.1.Individuals
heterozygous for the defective allele are EMs with some
impairment in effecting this reaction, indicating a
gene–dose effect. Some phenotypically EM individuals
inherit alleles (eg,CYP2D6*10 and CYP2D6*17),which
express enzyme with reduced or altered affinity for certain
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11,12Within the EMs,there is another
subgroup, termed the ultrarapid metabolizers, resulting
from multiple copies of the gene for normal metabolic
capacity.
13The CYP2D6 gene is extremely polymorphic
with more than 70 allelic variants described so far.
14
The pharmacokinetic consequences of CYP2D6 poly-
morphism,shown in Table I,are that,relative to EMs,the
PMs experience far greater exposure to the parent drug,
15
while the reverse is true for the metabolites generated by
this enzyme.Ultrarapid EMs metabolize CYP2D6 sub-
strates so fast that, even at the usually recommended
doses,they are exposed to rapidly accumulating levels of
metabolites and manage to attain only very low plasma
levels of the parent drug.The importance of this poly-
morphism arises from the fact that the substrates of
CYP2D6 are typically the cardiovascular and psychoac-
tive drugs,most of which have a narrow therapeutic index
and are usually intended for long-term administration.
Table II summarizes the clinical consequences of
CYP2D6 polymorphism.It has been shown that PMs are
at risk of a number of side effects of drugs that are pri-
marily metabolized by CYP2D6.In contrast,many EMs,
including ultrarapid metabolizers,are at risk of exagger-
ated pharmacological effects of the metabolite and much
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Table I. Pharmacokinetic consequences of the drug-metabolizing enzyme
CYP2D6 polymorphism. PM, poor metabolizer; EM, extensive
metabolizer; Cmax, peak concentration; AUC, area under the
curve.
Pharmacokinetic parameter Consequences for the PM
relative to the EM
• Bioavailability 2- to 5-fold
• Systemic exposure
Cmax 2- to 6-fold
AUC 2- to 5-fold
• Half-life 2- to 6-fold
• Metabolic clearance 0.1- to 0.5-fold
Table II. Clinical consequences for poor metabolizer (PM) and ultrarapid extensive metabolizer (EM) phenotypes of the drug-metabolizing enzyme
CYP2D6. CNS, central nervous system.
Clinical consequences for the PM
• Increased risk of toxicity
Debrisoquine Postural hypotension and physical collapse
Sparteine Oxytocic effects
Perphenazine Extrapyramidal symptoms
Flecainide Ventricular tachyarrhythmias?
Perhexiline Neuropathy and hepatotoxicity
Phenformin Lactic acidosis
Propafenone CNS toxicity and bronchoconstriction
Metoprolol Loss of cardioselectivity
Nortriptyline Hypotension and confusion
Terikalant Excessive prolongation in QT interval
L-Tryptophan Eosinophilia-myalgia syndrome
Indoramin Sedation
Thioridazine Excessive prolongation in QT interval
• Failure to respond
Codeine Poor analgesic efficacy
Tramadol Poor analgesic efficacy
Opiates Protection from oral opiate dependence
Clinical consequences for the ultrarapid EM
• Increased risk of toxicity
Encainide Proarrhythmias?
Codeine Morphine toxicity
• Failure to respond
Nortriptyline Poor efficacy at normal doses
Propafenone Poor efficacy at normal dosesattenuated effects of the parent drug. CYP2D6 poly-
morphism has efficacy implications as well.PMs are at a
risk of lack of efficacy when the therapeutic effect of a
drug is mediated principally by its CYP2D6-generated
metabolite.
The CPMP guideline
16 on “Pharmacokinetic Studies in
Man”has included direct references to genetic factors for
well over 15 years now! This guideline requires that meta-
bolic studies should indicate whether the metabolism of
a drug may be substantially modified in case of genetic
enzyme deficiency and whether within the dose levels
normally used, saturation of metabolism may occur,
thereby resulting in nonlinear kinetics.It is therefore self-
evident that if a new antipsychotic drug under develop-
ment is found to be metabolized by an enzyme that is
polymorphic, every attempt should be made during its
development to determine whether the clinical response
to it—therapeutic or toxic—is determined or heavily
influenced by genetic factors. In this context, it may be
noted that there is some concern arising from the evi-
dence that clinical trial population may be biased by an
inappropriate underrepresentation (or even absence) of
specific genotypes, usually the PMs.
17,18 Others have
argued for prescreening genotyping of subjects with a
view to actively excluding specific genotypes from clini-
cal trials.
18
A wide range of neuroleptic drugs are metabolized by
CYP2D6.However,studies investigating the relationship
between CYP2D6 phenotype or genotype and response
to these drugs have provided ambiguous evidence on the
utility of genotyping patients to predict drug response.
The author of this paper analyzed 17 studies published
between 1995 and 2000, which had included over 1350
patients receiving a range of neuroleptic drugs (R.Shah,
manuscript in preparation).These studies investigated
the association between CYP2D6 genotype and drug lev-
els, failure to respond beneficially, and frequency and
severity of a number of adverse reactions (neuroleptic
malignant syndrome,extrapyramidal symptoms [EPS],
and TD).Relationship with plasma concentrations was
shown for drugs with dominant CYP2D6-mediated
metabolism,but large intragenotypic variability tended
to obscure its clinical value.However,there was no rela-
tionship reported for failure to respond beneficially.
There was a general modest trend observed towards a
positive correlation between the genotype,especially the
presence of *10 allele in the Japanese,and severity of TD
and EPS.This discouraging finding is hardly surprising,
since many antipsychotic agents are metabolized by mul-
tiple pathways and many have active metabolites.It is,
however,acknowledged that these studies were highly
heterogeneous,investigating a variety of drugs,regard-
less of the pharmacokinetics, pharmacodynamics, and
pharmacokinetic/pharmacodynamic relationships of the
drugs and their metabolites.Dahl has recently reviewed
the relevance of CYP2D6 and other genetic polymor-
phisms of drug-metabolizing enzymes in relation to clin-
ical response to antipsychotic therapy,
11 reaching essen-
tially the same conclusion as this author. Another
important area of interest in pharmacogenetics has
focused on candidate genes of the pharmacological tar-
gets that play a role in susceptibility to TD. Four pub-
lished studies have investigated an association between
a Ser9Gly polymorphism in exon 1 of the dopamine D3
receptor gene (DRD3) and TD;three failed to show an
association and one found an insignificant trend.Lerer
et al
19 examined this association in a pooled sample of
780 patients (317 with TD and 463 without TD).Their
findings support a small but significant contribution of
the DRD3 Ser9Gly polymorphism to TD susceptibility,
which is demonstrable over and above population effects
and the effect of age and gender on the phenotype.
Arising from the globalization of drug development pro-
grams,the global heterogeneity in the frequencies of var-
ious variant alleles in different populations has become
an important regulatory issue. The ICH guideline
20 on
“Ethnic Factors in the Acceptability of Foreign Clinical
Data”recommends evaluation of the clinical trials data
from one region or population for their extrapolation to
another region or population. To this end, it is recom-
mended that the submission should include (i) adequate
characterization of pharmacokinetics,pharmacodynam-
ics,dose–response,efficacy,and safety in the population
of the foreign region; and (ii) characterization of phar-
macokinetics,pharmacodynamics,and dose–response in
the new region. The guideline recognizes the role of
genetic factors and the slope of the dose–response curve
in determining whether the drug is likely to show signifi-
cant ethnic differences during clinical use.When inter-
ethnic differences are anticipated,bridging studies may
be required.
Proarrhythmic effects of neuroleptics
The QT interval of the electrocardiogram (ECG) reflects
the duration of the ventricular action potential.It is pro-
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reduction in outward potassium current during phases 2
and 3 of the action potential.The delayed rectifier potas-
sium channel (IKr) is primarily responsible for mediating
this repolarizing current.Four HERG (human ether-a-go-
go) α-subunits assemble with miRP1 β-subunits to form
IKr.In in vitro studies,blockade of HERG is predictive
of the blockade of IKr.Almost all drugs (including the
neuroleptics) that prolong the QT interval do so by block-
ing this channel.This action,when exerted in a carefully
controlled manner,is the primary pharmacological mech-
anism by which class III antiarrhythmic drugs exert their
therapeutic effect.However,QT interval prolongation,
when excessive,can be proarrhythmic and can degener-
ate into TdP,a unique form of polymorphic ventricular
tachycardia.
21Apart from clinical manifestations resulting
from impaired circulation,TdP is potentially fatal.TdP
subsequently degenerates into ventricular fibrillation in
about 20% of cases
22 and,not uncommonly,cardiac arrest
and sudden death may be the outcome.
23The overall mor-
tality from TdP is of the order of 10% to 17%.
22,24 Drug-
induced prolongation of QT interval is,therefore,a highly
undesirable pharmacological effect as far as nonanti-
arrhythmic drugs are concerned.Clinically,a number of
antianginal drugs as well as noncardiovascular drugs have
been shown to possess this concentration-related unde-
sirable pharmacological activity.There are now well over
10 antianginal and 100 noncardiac drugs that have been
reported to significantly prolong the QT interval and/or
induce TdP.
25 Unfortunately, neuroleptic drugs feature
prominently in this list.In a survey of 2194 cases of TdP
in the FDA database recorded from 1969 to 1998, psy-
choactive drugs were held culpable in 21.9% of cases.
24 Of
these 2194,11.7% were associated with drug interactions
and a further 9.2% with overdoses. Haddad and
Anderson have also recently reviewed the data on
antipsychotic-related QTc interval, TdP, and sudden
death.
26 Patients prescribed moderate doses of antipsy-
chotics have large relative and absolute increases in the
risk of sudden cardiac death.Data from one large retro-
spective Medicaid study suggest that the potential adverse
cardiac effects of antipsychotics are significantly greater
in patients with cardiovascular disease.
27
It is recognized that QT interval prolongation per se is
not necessarily harmful.It is only harmful when the pro-
longation is excessive enough to degenerate into TdP.The
proarrhythmic threshold for QTc interval is close to 500
ms and the risk of induction of TdP bears an exponential
relationship to the degree of prolongation above this
threshold.The link between QT interval prolongation
and TdP is complex and influenced by many other fac-
tors.
25 Myxedema is also associated with prolongation of
QT interval, but this is not a disease that one typically
associates with TdP! Not all the drugs prolonging the QT
interval,or blocking the outward repolarizing potassium
current to the same extent,carry the same torsadogenic
risk.Drugs such as amiodarone and racemic sotalol pro-
long the QT interval,but their torsadogenic potential is
nowhere near as high as one might anticipate.
Notwithstanding, QT interval is the best surrogate
marker we currently have for TdP that,by definition,is
associated with and follows concurrent prolongation of
the QT interval.The level of risk varies with each neu-
roleptic, with thioridazine being highly torsadogenic.
Although ziprasidone has been shown to block the
HERG channel in vitro and prolong the QTc interval in
vivo in man,there have been no reported cases of TdP
associated with its clinical use to date.A fuller picture will
only emerge following its wider use.Other ancillary phar-
macological properties of these drugs,particularly auto-
nomic effects,no doubt,modulate their torsadogenic risk.
While (+)-(S)-sotalol is highly torsadogenic, racemic
sotalol is much less so because of the β-blocking activ-
ity of (-)-(R)-sotalol in the racemic drug.
28,29 Sertindole
too markedly prolongs the QT interval,but its powerful
α-adrenoceptor (and possibly calcium channel)–blocking
activity seems to offer a relative protection against the
development of TdP.In one study of 1444 patients receiv-
ing a mean (SD) daily dose of 13.4 (5.6) mg sertindole,
there were 15 reports of QTc interval prolongation with
no cases of TdP.
30
The risk is further modified by a number of other factors
such as bradycardia, diminished basal repolarization
reserve (as in congenital QT interval prolongation syn-
dromes),cardiac disease,or electrolyte imbalance.In one
study of 313 schizophrenic men, admitted on an emer-
gency basis during a 24-month period,serum potassium
concentration in the severely agitated group was lower
than that in the mildly affected group.There was a signif-
icant inverse correlation between serum potassium con-
centration and the level of symptoms of acute agitation.
Improvement in serum level following sedation correlated
with baseline acute agitation.
31 An association is docu-
mented between hypokalemia and acute psychotic decom-
pensation in a patient with chronic schizophrenia.
32 Some
recent clinical studies also indicate that hypokalemia is a
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455characteristic feature in acute psychotic patients at the
time of emergency admission.Since hypokalemia is one of
the major causes of prolonged QT interval and TdP,it was
not surprising to find that in 67 drug-free acute psychotic
patients,the mean QTc interval was prolonged.The mean
QTc interval of psychiatric emergency patients was longer
than that of psychiatric outpatients.As psychiatric emer-
gency patients often receive parenteral antipsychotics,it is
evident why the QT-prolonging activity of a new neu-
roleptic agent should be thoroughly characterized.
33
Mutations of potassium channels,resulting in diminished
repolarization reserve and increased pharmacodynamic
susceptibility to QT prolongation,are common.There is
now a wealth of evidence that,in view of the low penetra-
tion of many of these mutations, the size of population
with mutations of potassium channels may be substantially
larger than that diagnosed by ECG recording alone.
Relatively large numbers of individuals who carry these
“silent”mutations of long QT syndrome genes have been
identified.
34They have a diminished repolarization reserve,
but a normal ECG phenotype.They are nevertheless at an
increased proarrhythmic risk, often developing TdP at
therapeutic doses. It has been postulated that drug-
induced long QT syndrome might represent a genetically
mediated forme fruste of the long QT syndrome.
Furthermore,any cardiac disease-induced downregula-
tion of potassium channels will also increase this suscep-
tibility to proarrhythmias.Female gender is a particularly
striking example of genetically conferred susceptibility.
In view of the potentially fatal outcome (even when TdP
follows the use of antiarrhythmic drugs),the regulatory
focus on the effect of drugs on QT interval has shifted
dramatically from one of a beneficial antiarrhythmic
mechanism to that of a highly undesirable pharmacolog-
ical activity.Given the wide range of drugs from diverse
chemical and pharmacotherapeutic classes that are
known to be associated with potential to prolong the
QTc interval, it is important that all NCEs are charac-
terized,during preclinical and clinical development,for
their effect on cardiac repolarization.In December 1997,
the CPMP adopted two documents of considerable sig-
nificance for the development of neuroleptic drugs.
One of these was the CPMP document “Points to
Consider: The Assessment of the Potential for QT
Interval Prolongation by Noncardiovascular Medicinal
Products.”
35This describes the preclinical and clinical trial
strategy for investigation of drugs for their potential to
prolong the QT interval.Clinical trials designed to inves-
tigate the QT liability of an antipsychotic agent are a
major challenge in drug development. This is largely
because QTc interval shows considerable spontaneous
intraindividual variability and is susceptible to a number
of nonpharmacological influences.
Healthy volunteer studies are the first to be undertaken
during clinical development and are more robust when
of crossover design.The doses used in healthy volunteer
studies should be reasonable multiples of the likely rec-
ommended dose (to ascertain its dose–effect relation-
ship),in both the absence and presence of a metabolic
inhibitor. Depending on the half-life of the drug, the
study should be of an appropriate duration.It is prudent
to include a positive control and the study should be
appropriately powered to detect not only the difference
in changes in mean QTc interval,but also the frequency
of outliers as defined in the CPMP document (especially
those with a QTc interval of ≥500 ms or those with an
increase in QTc interval of ≥60 ms from baseline).The
QT interval should be carefully measured by blinded
readers and the values corrected for changes in heart rate
by not only the traditional Bazett’s correction,but also
the Fridericia correction and,if practical,by a study-spe-
cific correction formula.
Although these studies are conducted in healthy volun-
teers,ECGs should also be rigorously monitored in all
patients in phase 2 studies and in a substantial number in
phase 3 studies. The demography of these patients in
terms of age, gender, comedications, and comorbidity
should be representative of the ultimate target popula-
tion.
The data from these clinical studies must be interpreted
collectively together with preclinical in vitro and in vivo
data.
25 It is important that the regulatory submission
package addresses the issues on the roles of dose sched-
ules, metabolites, stereoselectivity in cardiotoxicity,
comedications (drug interactions),comorbidity,pharma-
cogenetic factors,and if relevant,product formulation.
Drug interactions and neuroleptics
A number of drugs such as terfenadine, astemizole,
pimozide, cisapride, and others have the propensity to
prolong the QT interval and induce TdP and other proar-
rhythmias,more often (but not always) as a result of drug
interactions.Therefore,the other significant document
adopted by the CPMP was its “Note for Guidance on the
Investigation of Drug Interactions.”
36
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456During concurrent administration of a drug with its
metabolic inhibitor to a normal EM, there follows the
pharmacokinetic (and often pharmacodynamic) conse-
quences that are usually observed in the PM genotype.
For example,inhibition of CYP2D6 (eg,by administra-
tion of quinidine,a potent CYP2D6 inhibitor) in a nor-
mal EM genotype converts the subject into a PM phe-
nocopy, predisposing the individual concerned to
developing high plasma concentrations of,and a much
greater systemic exposure to,the substrate parent drug.
Apart from quinidine,a large number of other drugs are
also known to inhibit CYP2D6.Among the most power-
ful inhibitors of CYP2D6 are fluoxetine,
37 other selective
serotonin reuptake inhibitors,
38 and moclobemide.
39The
inhibition of CYP2D6 by these popular drugs is critical,
given that typical substrates of CYP2D6 are cardiovas-
cular and psychoactive drugs with narrow therapeutic
index and most likely to be coprescribed to the elderly.
Furthermore,one substrate of CYP2D6 may inhibit the
metabolism of another CYP2D6 substrate through com-
petition for the drug-metabolizing site.Similarly,inhibi-
tion of other cytochrome P450 enzymes by their corre-
sponding inhibitors results in functional PMs of the
metabolic pathways mediated by those enzymes. One
inhibitor may inhibit more than one cytochrome P450
enzyme.
Just as administration of an inhibitor to an EM genotype
converts the subject into a PM phenocopy,the adminis-
tration of an inducer to a normal EM produces a pheno-
copy of an ultrarapid EM.Induction is usually not a fea-
ture of CYP2D6, but it is most evident with CYP3A4.
Drugs such as rifampicin,phenytoin,and other anticon-
vulsants are powerful inducers of CYP3A4. Induction
results in rapid elimination of the parent drug and rapidly
accumulating metabolites. Metabolites of drugs can at
times be even more powerful and/or unexpected
inhibitors.
Drug interactions are probably more frequent than one
might realize.It is estimated that adverse reactions,drug
interactions, and contraindications account for 55.8%,
9.0%,and 5.8%,respectively,of all safety-related changes
to product particulars during the postapproval period of
a drug. However, it is estimated that 6.9% to 22% of
adverse drug reactions are in fact due to drug interac-
tions. One investigation from Sweden studied the
CYP2D6 genotype on postmortem femoral blood from
22 cases in whom there was unexpectedly high ratio of
parent drug to metabolite.None was found to be a geno-
type PM. Clearly, this high ratio of parent drug to
metabolite had resulted from inhibition of metabolism
due to drug interactions. In contrast, there was 1 PM
among the 24 other cases serving as controls (represent-
ing a PM frequency of 4.2% in this control population
versus the general population frequency of 4% to 5%
PMs).
Drug interactions are of particular concern for drug
classes with a narrow therapeutic index or for drugs
known to modulate the activity of drug-metabolizing
enzymes.Consequently,there are certain major pharma-
cotherapeutic classes of drugs involved in clinically sig-
nificant drug interactions.One survey found that cardio-
vascular (40%), gastrointestinal (16%), neurological
(15%),hemopoietic (14%),respiratory (3%),and anti-
infective (3%) drugs were the major therapeutic classes
involved in drug interactions.There is little doubt that
drug interactions are on the increase.A number of fac-
tors account for this rise.
In the context of neuroleptic therapy,the foremost is the
extent of polypharmacy.In one survey among subjects
with schizophrenia,
40 an average number of 1.54 neu-
roleptics were prescribed per patient,compared with 1.4
and 1.2 in other psychotic and depressed subjects,respec-
tively.Regardless of the indication,nonneuroleptic psy-
chotropic drugs were coprescribed in 75.4% of cases,
mainly benzodiazepines (75.7%).Adjuvant drugs used in
prevention or treatment of side effects were coprescribed
in 46.7%, mostly anticholinergic drugs against parkin-
sonism (86.1%).The main finding of another survey was
that 27.5% of patients with schizophrenia were dis-
charged on an antipsychotic polypharmacy regimen.The
investigators concluded that although antipsychotic
polypharmacy persists today, as it has over the past 30
years,evidence-based data to support this controversial
treatment strategy are lacking.
41 On the basis of their
multinational study in inpatients with schizophrenia,
Kiivet et al
42 concluded that polypharmacy with con-
comitant multiple neuroleptics,additional anticholiner-
gic drugs,and other psychotropics is an international phe-
nomenon. At least two neuroleptics were prescribed
simultaneously on 73% of treatment days in Badajoz
(Spain) and 46% in both Huddinge (Sweden) and Tartu
(Estonia).
The issue of drug interactions is intricately linked with
pharmacogenetics.Since PMs do not have any functional
enzyme to inhibit,they are unlikely to display a pharma-
cokinetic interaction. Likewise, the probability of an
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457interaction is low in those with a high metabolic capacity
such as those who are homozygous extensive or ultra-
rapid metabolizers. These individuals have high func-
tional reserve and therefore,high (almost toxic) doses of
inhibitors may be required for adequate inhibition.The
subjects most likely to display an interaction are those
with compromised metabolic capacity (heterozygous
EMs).This genotype-dependent response accounts for
the recommendation in the CPMP guidance note
36 that
subjects enrolled in drug–drug interaction studies should
be genotyped.
The data from drug interaction studies should be pre-
sented not only in terms of the mean changes,but also in
terms of each individual.Data should also be presented on
metabolites and enantiomers when measured.The signif-
icance of the changes observed should be considered in
terms of their clinical relevance—notwithstanding any sta-
tistical significance of these changes—bearing in mind the
dose–concentration–response curves.Recommendations
for labeling should be formulated in light of these consid-
erations.
Evaluation of approvability and 
labeling implications
It is most unlikely that any neuroleptic NCE,however
unique,will be approved these days unless its regulatory
submission includes adequate studies—preclinical and
clinical—characterizing the potential of the NCE to pro-
long the QT interval. The strategy recommended for
investigating this potential is described in the CPMP doc-
ument referred to earlier.
35
Once it is concluded that the drug is likely to significantly
prolong the QTc interval at clinically relevant concen-
trations,the approval of the drug depends on a number
of factors.These include the potency and the frequency
of the QTc prolongation by the drug, the likely pro-
arrhythmic risk,the therapeutic indication supported by
the data, the susceptibility of the target population to
proarrhythmias,its overall safety profile,and the thera-
peutic benefit conferred by the NCE.
43 Availability of
alternatives with superior risk/benefit ratio is also an
important determinant of the approvability of the NCE
concerned.The careful balance of risk and benefit lead-
ing to the approval of a drug with a serious adverse drug
reaction is best illustrated by clozapine.The efficacy of
clozapine in patients who had failed to respond to other
drugs was sufficiently compelling that,despite a relatively
high frequency of myelosuppression associated with its
use, it was approved, subject to regular hematological
monitoring of the patient.
Labeling restrictions
It is not inconceivable that despite its potential to pro-
long the QT interval,a nonantiarrhythmic NCE may be
approved,provided a carefully planned clinical develop-
ment program has identified a population in whom the
benefits of the drug can be shown to outweigh the small
potential risk of proarrhythmias or the drug can be
shown to fulfil an unmet need.For such drugs,the pre-
scribing information (known as the summary of product
characteristics “SPC” in Europe and “labeling” in the
USA) would require careful crafting of the indication to
reflect the population and the disease entity most likely
to benefit as well as detailed information on the proar-
rhythmic risk with carefully selected dose regimen,
appropriate contraindications,description of interactions,
special precautions,and monitoring requirements during
their clinical use.
43
Reflecting the robust data on efficacy,restriction of an
indication may be one way of minimizing the population
likely to be exposed to the NCE.Allied to the indication
is the posology of the NCE.The posology section may be
required to include information on starting dose,a shal-
low dose titration schedule depending on the half-life of
the drug and the time required to reach steady state,
maximum single dose, maximum daily dose, and the
duration of therapy.
The most recent example of restriction of indications is
thioridazine. From July 2000, the indication for thiori-
dazine in the US was amended by the FDA to state:
“Thioridazine is now indicated only for schizophrenic
patients who fail to show an acceptable response to ade-
quate courses of treatment with other antipsychotic drugs,
either because of insufficient effectiveness or the inability
to achieve an effective dose due to intolerable adverse
effects.Thioridazine has not been systematically evaluated
in controlled trials in treatment-refractory schizophrenic
patients and its efficacy in such patients is unknown.”
In view of the long half-life of pimozide (55 h,but may
be as high as 150 h in some), its dose schedule was
revised to recommended a starting dosage of 20 mg/day
with a maximum dosage of 60 mg/day.Following reports
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ule of pimozide for chronic schizophrenia was re-
amended to recommend an initial starting dosage of 
2 mg/day (exceptionally 10 mg/day in acute schizophre-
nia,but even this recommendation too was subsequently
removed). The dose was to be increased by a shallow
dose titration (“dose increases should be made at weekly
intervals or longer, and by increments of 2-4 mg in the
daily dose”).The maximum dosage was reduced from 60
to 20 mg/day.
The section of the SPC most likely to be effective in con-
taining a clinical risk,if the prescribing physicians adhere
to it, is that on contraindications. In view of the many
pharmacological properties commonly shared by these
QT-prolonging drugs and the common features associ-
ated with drug-induced TdP, it is not surprising that a
standard set of contraindications have evolved over time.
These include those related to the pharmacokinetics of
the drug (comedication with inhibitors of the metabolism
of the drug and patients with hepatic and/or renal dys-
functions) and those related to enhanced susceptibility
to the undesirable pharmacodynamic effect of the drug
on cardiac repolarization (predisposition to hypokalemia,
bradycardia,cardiac disease,and/or arrhythmias,preex-
isting prolongation of QT interval, and comedication
with other QT-prolonging drugs).
Specific contraindications may also be applied to suit par-
ticular drugs.For example,since thioridazine is metabo-
lized by CYP2D6,it was determined that “thioridazine is
also contraindicated in patients known to have reduced lev-
els of cytochrome P4502D6.” Sertindole too is metabolized
by CYP2D6,but in PMs of CYP2D6,an alternative path-
way of elimination is that mediated by CYP3A4. Since
PMs of CYP2D6 may not be routinely identified in clini-
cal practice,it was considered essential that sertindole was
contraindicated with inhibitors of CYP3A4 generally in
order to specifically protect the PMs.
Special warnings and precautions may be required with
regard to the use of a QT-prolonging NCE in special
populations, such as patients with cardiac disease, the
elderly,or patients receiving diuretics and other relevant
drug classes.Statements may also be required on special
monitoring requirements. These may include ECG
recordings pretreatment and periodically while the
patient is on treatment.Pimozide,once again,illustrates
the case well.ECG monitoring is recommended at base-
line, annually, and (even more frequently) in those
patients receiving pimozide in excess of 16 mg/day. A
review of the need to continue treatment with pimozide
is recommended in those showing certain specified ECG
changes.The US labeling of thioridazine also requires
serum potassium levels to be measured and normalized
before starting treatment.It is also recommended that
patients with a QTc interval greater than 450 ms should
not receive thioridazine.It is further advised that peri-
odic monitoring of ECGs and serum potassium levels
during thioridazine treatment may be useful and thiori-
dazine should be discontinued in patients who are found
to have a QTc interval over 500 ms.
The interaction section of pimozide, for example,
describes pharmacodynamic interactions associated with
comedications,such as neuroleptics,risk of diuretic ther-
apy, drugs that prolong the QT interval, drugs with
arrhythmogenic potential (antidepressants,antiarrhyth-
mics), its CYP3A4- and CYP2D6-mediated metabolic
profile (including in vitro data) and the consequences of
the concurrent use of the inhibitors of its metabolism.
The labeling of sertindole includes an elaborate drug
interactions section describing its metabolism by
CYP2D6 and CYP3A4 and the probable interactions at
these loci.
The undesirable effects section should include details of
the QTc interval changes and arrhythmias observed in
clinical trials and,if appropriate,clinical manifestations
of these arrhythmias.Statements on the magnitude of the
risk,risk factors,and course of action in the event of an
arrhythmia may also be required if the information is
available.The US labeling of perphenazine includes a
reminder of the potential value of pretreatment geno-
typing of the elderly patients for their CYP2D6 status
with a view to identifying those at high risk of adverse
effects.
Finally,the overdose section should include information
on acute toxicity experience in animals,any observations
during clinical trials,dose for proarrhythmic risk,dura-
tion of risk, special clinical manifestations, monitoring
recommendations, measures to reduce systemic expo-
sure,and the role of dialysis.
Effectiveness of prescribing restriction
An important question in approving the drugs with “QT
liability,”even with a restrictive labeling,is how effective
these prescribing restrictions are in containing the risk of
potentially fatal TdP.Recent experiences with terfena-
dine and cisapride are not very encouraging.
44-46 It is also
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459questionable whether the patients will be appropriately
monitored.It is remarkable how few patients receiving
even high doses of antipsychotic agents are being moni-
tored by ECGs as recommended in the prescribing infor-
mation.
47 In evaluation of the proarrhythmic risks of a
QT-prolonging drug during its routine clinical use and its
approval, it has now become essential also to consider
whether the prescribing information,however restrictive,
is practical and likely to be adhered to.
Conclusions
The development of safe and effective new drug treat-
ments for schizophrenia poses a challenging task.This
class of drugs have a wide range of serious and trouble-
some side effects and usually a narrow therapeutic index
with active metabolites.These features make it impera-
tive that the optimal dose schedules are carefully charac-
terized during drug development.Advances in genomics
have raised the expectations of individualized therapy.In
terms of drug development,characterizing the dose and
individualizing therapy is made more complex by the
polymorphisms of enzymes that metabolize many of these
drugs and their pharmacological targets.Many neurolep-
tic agents are proarrhythmic with an adverse effect on
cardiac repolarization.They are prone to prolonging the
QT interval and inducing potentially fatal TdP.This makes
it imperative that all new neuroleptic agents are thor-
oughly explored for their proarrhythmic potential.The
clinical use of many of these drugs is fraught with a high
potential for drug–drug interactions,which should also be
adequately investigated during their development.The
approvability and the labeling of any new neuroleptic
agent require a careful assessment of its risk/benefit ratio
and that of available alternatives.Neuroleptic drugs,like
other drugs,are approved on the understanding that the
risks can be managed and contained effectively by their
appropriate use and supervision of the patients.Patients
require to be monitored as recommended for any cardiac
electrophysiological effects and for other side effects.
Provided the physician adheres to the prescribing infor-
mation,neuroleptics may be used safely and effectively in
routine clinical practice. ❏
I wish to express my gratitude to my colleagues, Prof Barry Lebowitz, Prof
John Lewis, and Dr Sarah Branch, for their helpful and very constructive
comments. The views expressed in this paper are those of the author and
do not necessarily represent the views or the opinions of the Medicines
Control Agency, other regulatory authorities, or any of their advisory com-
mittees.
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Desarrollo de agentes neurolépticos: 
farmacogenética y aspectos actuales de
seguridad de importancia para las agencias
reguladoras
El desarrollo de nuevos tratamientos con fármacos
seguros y efectivos para la esquizofrenia implica
una tarea desafiante. Se sabe que esta clase de fár-
macos se asocia con un amplio margen de serios y
molestos problemas de seguridad que incluyen
efectos neurológicos, cardíacos, endocrinos y meta-
bólicos. Muchos de estos fármacos tienen un estre-
cho índice terapéutico y generan metabolitos que
a menudo tienen un perfil farmacológico específico
el cual difiere del compuesto madre. Estas caracte-
rísticas determinan en forma imperativa que los
esquemas de dosis óptimas para los neurolépticos
sean cuidadosamente individualizados. Muchos de
estos fármacos son metabolizados por enzimas cito-
cromo P450, las que tienen un polimorfismo gené-
tico y una distribución bimodal dentro de la pobla-
ción. Un subgrupo significativo de la población no
puede eliminar estos fármacos en forma tan efec-
tiva como la mayoría. Esto conlleva un aspecto adi-
cional de complejidad al tener que caracterizar la
dosis e individualizar la terapia. Muchos agentes
neurolépticos son proarrítmicos, con un efecto
adverso en la repolarización cardíaca. Ellos son pro-
clives a prolongar el intervalo QT y a inducir “tor-
sade de pointes.” Dada la evolución potencial-
mente fatal de esta taquiarritmia ventricular, los
programas de desarrollo de fármacos requieren
asegurar que el potencial proarrítmico de cualquier
nuevo agente neuroléptico sea completamente
explorado y se caracterice su riesgo proarrítmico. El
uso clínico de muchos de estos fármacos se complica
además por su alto potencial de interacciones fár-
maco-fármaco. Esto también requiere ser adecua-
damente investigado durante el desarrollo. La apro-
bación y rotulación de un nuevo agente
neuroléptico requiere de una cuidadosa evaluación
por las agencias de regulación de su relación riesgo-
beneficio en comparación con las alternativas tera-
péuticas disponibles. Su empleo seguro y efectivo
en la práctica clínica rutinaria depende de una
atención cuidadosa a la información para prescribir,
especialmente respecto a contraindicaciones, pre-
cauciones y requisitos de monitoreo del paciente.
Développement des neuroleptiques : 
pharmacogénétique et aspects réglementaires
actuels concernant la sécurité d'emploi
Le développement de nouveaux traitements médi-
camenteux sûrs et efficaces pour la schizophrénie est
un défi. Cette classe de médicaments est connue
pour être associée à un large éventail de problèmes
sérieux et gênants concernant la sécurité d’emploi
tels que des effets indésirables neurologiques, car-
diaques, endocriniens et métaboliques. Un grand
nombre de ces médicaments ont un index théra-
peutique étroit et génèrent des métabolites qui ont
souvent leur propre profil pharmacologique original
et différent de la molécule mère. Ces particularités
imposent que les schémas posologiques optimaux
soient soigneusement définis. Un grand nombre de
ces médicaments sont métabolisés par les enzymes
du cytochrome P450, qui montrent un polymor-
phisme génétique et une distribution bimodale dans
la population. Un sous-groupe important de la popu-
lation ne peut pas éliminer ces médicaments aussi
efficacement que la majorité. Cela apporte une
dimension supplémentaire dans la complexité pour
déterminer la dose et personnaliser le traitement.
Beaucoup de neuroleptiques sont arythmogènes
avec un effet indésirable sur la repolarisation car-
diaque et sont susceptibles d’allonger l’intervalle QT
et d’induire des torsades de pointes. Étant donné l’is-
sue fatale possible d’une telle tachyarythmie ventri-
culaire, les programmes de développement d’un
médicament doivent garantir que le potentiel
arythmogène de tout nouveau neuroleptique a été
complètement exploré et ses risques arythmogènes
définis. Par ailleurs, le risque élevé d’interactions
médicamenteuses perturbe l’utilisation clinique d’un
grand nombre de ces médicaments. Celles-ci doivent
aussi être correctement explorées pendant le déve-
loppement. L’approbation et l’étiquetage de condi-
tionnement d’un nouveau neuroleptique deman-
dent une évaluation réglementaire soigneuse du
rapport bénéfice/risque à comparer aux choix exis-
tants. L'innocuité et l'efficacité en pratique clinique
de routine des neuroleptiques dépendent de l’at-
tention vigilante portée à l’information contenue
dans leurs fiches signalétiques respectives, en parti-
culier concernant les contre-indications, les précau-
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